A Phase 1, Open-label, Multi-center Study to Determine the Pharmacokinetics and Safety of Solithromycin as Add-on Therapy in Adolescents and Children With Suspected or Confirmed Bacterial Infection
Phase of Trial: Phase I
Latest Information Update: 17 Apr 2019
Price : $35 *
At a glance
- Drugs Solithromycin (Primary) ; Solithromycin (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Cempra Pharmaceuticals; Melinta Therapeutics
- 11 Jun 2018 Results assessing combined PK data from 2 phase I studies (NCT01966055 and NCT02268279) published in the Antimicrobial Agents and Chemotherapy
- 13 Nov 2016 Status changed from recruiting to completed.
- 12 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Oct 2016.